Immunogenicity, Safety, and Clinical Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)

Immunogenicity, Safety, and Clinical Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine in Patients With Spondyloarthritis (Preliminary Data)

Background. Immunosuppressive drugs are widely used for the treatment of patients with spondyloarthritis (SpA) to effectively control the activity of the disease. At the same time, the use of these drugs is associated with an increased risk of developing infections of the upper and lower respiratory...

Full description

Saved in:
Bibliographic Details
Main Authors: M. M. Baranova, N. V. Muravyeva, B. S. Belov, M. V. Cherkasova, Zh. G. Verizhnikova, T. V. Korotaeva
Format: Article
Language:Russian
Published: LLC "Publishing House OKI" 2022-04-01
Series:Антибиотики и Химиотерапия
Subjects:
pneumococcal infection
spondyloarthritis
23-valent pneumococcal polysaccharide vaccine
immunogenicity
safety
clinical efficacy
Online Access:https://www.antibiotics-chemotherapy.ru/jour/article/view/888
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items